

Res. Asst. BAHAR ARSLAN

Personal Information

Office Phone: [+90 352 207 6666](tel:+903522076666)

Email: bahararslan@erciyes.edu.tr

Web: <https://avesis.erciyes.edu.tr/bahararslan>

Address: bahararslan@erciyes.webmail.com

International Researcher IDs

ORCID: 0000-0002-2786-8489

Biography

1980 yılında Elazığ'da doğdum. İlkokul Evrenpaşa İlkokulunda okudum.

Ortaokul ve lise eğitimimi Elazığ Anadolu Lisesinde tamaladım.

2004 yılında Fırat Üniversitesi Tıp Fakültesinden mezun oldum

2009 yılında Fırat Üniversitesi Tıp Fakültesinde göğüs hastalarını ve Tüberküloz Anabilim Dalında uzmanlık eğitimimi tamamladım.

2010-2018 tarihleri arasında Kayseri Eğitim ve Araştırma Hastanesinde uzman doktor olarak;

2018-2020 yılları arasında Kayseri Şehir Hastanesinde uzman doktor olarak görev yaptım.

Education Information

Post Doctorate of Medicine, Erciyes University, Tıp Fakültesi, Dahili Tıp Bil., Turkey 2020 - Continues

Research Areas

Health Sciences

Academic Titles / Tasks

Research Assistant, Erciyes University, Tıp Fakültesi, Dahili Tıp Bil., 2020 - Continues

Published journal articles indexed by SCI, SSCI, and AHCI

- I. Doxycycline may be more clinically effective in type 2 chronic rhinosinusitis nasal polyp comorbid with asthma
PAÇACI ÇETİN G., ARSLAN B., YILMAZ İ.
JOURNAL OF ASTHMA, vol.61, no.1, pp.20-26, 2024 (SCI-Expanded)

- II. **Characteristics of asthma in an older adult population according to sex and control level: why are asthma symptoms in older women not well-controlled?**
 KARADOĞAN D., YILMAZEL UÇAR E., YAVUZ Y., BAÇÇIOĞLU A., Oeztuerk A. B., Bozkurt N., Kavas M., Karaoglanoglu S., Celik G., AYDIN Ö., et al.
 JOURNAL OF ASTHMA, 2023 (SCI-Expanded)
- III. **The Role of Long-Acting Antimuscarinic Agents in the Treatment of Asthma**
 ARSLAN B., PAÇACI ÇETİN G., YILMAZ İ.
 JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, vol.36, no.4, pp.189-209, 2023 (SCI-Expanded)
- IV. **Discontinuing Omalizumab Treatment in Super-Responder Patients with Allergic Severe Asthma: Can the Baseline Total IgE Level Be Used as a Biological Marker to Decide Discontinuing Omalizumab Treatment?**
 ARSLAN B., PAÇACI ÇETİN G., Turk M., GÜLMEZ İ., YILMAZ İ.
 INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, vol.183, no.10, pp.1071-1077, 2022 (SCI-Expanded)
- V. **Anti-IL5/IL5R switching between biologics in patients with severe eosinophilic asthma**
 YILMAZ İ., Çetin G. P., ARSLAN B.
 Journal of Allergy and Clinical Immunology: In Practice, vol.10, no.7, pp.1935-1936, 2022 (SCI-Expanded)
- VI. **Venom immunotherapy and difficulties encountered before and during immunotherapy: Double sensitization, systemic reactions, treatment with omalizumab, and high dose VIT**
 PAÇACI ÇETİN G., YILMAZ İ., Turk M., ARSLAN B., Bahcecioglu S. N.
 TURKISH JOURNAL OF MEDICAL SCIENCES, vol.52, no.4, pp.1223-1234, 2022 (SCI-Expanded)
- VII. **Effectiveness of mepolizumab therapy on symptoms, asthma exacerbations, steroid dependence, and small airways in patients with severe eosinophilic asthma**
 YILMAZ İ., Nazik Bahcecioglu S., Turk M., TUTAR N., PAÇACI ÇETİN G., ARSLAN B.
 TURKISH JOURNAL OF MEDICAL SCIENCES, vol.51, no.4, pp.1953-1959, 2021 (SCI-Expanded)

Articles Published in Other Journals

- I. **Biological therapy management from the initial selection of biologics to switching between biologics in severe asthma**
 YILMAZ İ., ÇETİN G. P., ARSLAN B., ŞEKER S., YILMAZ H. E. B., AKTAŞ E., köylüce s., ACAR E.
 Tüberküloz ve Toraks, vol.71, no.1, pp.75-93, 2023 (ESCI)
- II. **Mepolizumab-Related Adverse Events in Severe Eosinophilic Asthma: A Real-Life Study**
 NAZİK BAHÇECİOĞLU S., TURK M., ATAYIK E., PAÇACI ÇETİN G., ARSLAN B., GÜLMEZ İ., YILMAZ İ.
 ASTIM ALLERJİ IMMUNOLOJİ, vol.20, no.2, pp.81-86, 2022 (ESCI)
- III. **Are we entering an era of combined biologic use for severe asthma?**
 ARSLAN B., ŞEKER S., YILMAZ İ.
 Tüberküloz ve Toraks, vol.70, no.4, pp.403-404, 2022 (ESCI)
- IV. **Safety Profiles of Biological Therapies Used in Asthma Treatment**
 PAÇACI ÇETİN G., ARSLAN B., YILMAZ İ.
 ASTIM ALLERJİ IMMUNOLOJİ, vol.20, no.3, pp.127-141, 2022 (ESCI)
- V. **The Management of Acute and Chronic Urticaria**
 YILMAZ İ., PAÇACI ÇETİN G., ARSLAN B., Turk M.
 ASTIM ALLERJİ IMMUNOLOJİ, vol.20, no.3, pp.202-204, 2022 (ESCI)
- VI. **Classification of asthma severity: Severe/not severe asthma or mild/moderate/severe asthma?**
 YILMAZ İ., Cetin G. P., ARSLAN B.
 TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, vol.70, no.3, pp.300-301, 2022 (ESCI)
- VII. **Blood hyperreosinophilia: A diagnostic challenge**
 PAÇACI ÇETİN G., KÖSE M., ARSLAN B., YILMAZ İ.
 TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, vol.69, no.3, pp.408-415, 2021 (ESCI)

VIII. Type 2 inflammation in asthma

YILMAZ İ., ARSLAN B.

TUBERKULOZ VE TORAKS-TUBERCULOSIS AND THORAX, vol.69, no.1, pp.114-115, 2021 (ESCI)

Supported Projects

YILMAZ İ., AYDIN Ö., ÇELEBİ SÖZENER Z., PAÇACI ÇETİN G., ARSLAN B., Project Supported by Higher Education Institutions, Kuaförlerde mesleksel allerjik hastalıkların değerlendirilmesi, 2021 - 2023

Metrics

Publication: 18

Citation (WoS): 19

Citation (Scopus): 21

H-Index (WoS): 2

H-Index (Scopus): 2